E2F1 has been attributed to numerous cancer hallmarks in prostate cancer, including cell cycle, proliferation and apoptosis [45], and its expression is so closely aligned with disease stage that it has been proposed as a potential biomarker [46,47]. Here, E2F1 is linked to prostate carcinoma.